Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630117 · ClinicalTrials.gov registry record · Phase 1
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
NCT06630117: Completed Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT06630117 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 245 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (308% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06630117, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
Study Summary
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection site AEs will be recorded on a vaccination report card (VRC).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL V330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-10-17 |
| Phase | Phase 1 |
What the finished NCT06630117 record still lists
NCT06630117 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (308% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06630117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06630117 about?
NCT06630117 is a clinical study titled "A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)". The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
What is the current status of trial NCT06630117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2024-03-01. Estimated completion is 2025-10-17.
What interventions are being tested in trial NCT06630117?
The interventions under investigation include: Placebo (BIOLOGICAL), V330 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06630117?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06630117's enrollment target sits among peer trials
245 189th of 2000 higher than 1,810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI